CD8A and neoplasm: Taken together, this flow cytometry analysis demonstrated distinct pharmacodynamic changes elicited by BETi+SMACm co-treatment which correlated with increased tumor control, enhanced CD8a+ T cell immunity, and reduced immunosuppressive cell types—such as PMN-MDSCs, arginase-1-expressing TAMs, and Ly-6C+ CAFs.